Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:IBRX NASDAQ:RGC NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$47.11+0.3%$39.08$21.72▼$48.68$8.94B1.153.06 million shs723,038 shsIBRXImmunityBio$2.75+0.2%$2.74$1.83▼$7.48$2.43B0.086.29 million shs3.38 million shsRGCRegencell Bioscience$14.68+7.2%$0.00$0.08▼$83.60$7.26B2.2913.33 million shs786,027 shsVRNAVerona Pharma PLC American Depositary Share$104.78+0.0%$85.24$18.51▼$104.99$8.92B0.241.70 million shs4.77 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-1.51%+8.75%+18.07%+38.76%+68.71%IBRXImmunityBio-5.52%+1.11%-10.75%+10.48%-56.92%RGCRegencell Bioscience-6.68%-29.05%+1,369,999,900.00%+1,369,999,900.00%+1,369,999,900.00%VRNAVerona Pharma PLC American Depositary Share+0.10%+20.62%+13.63%+79.71%+387.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.631 of 5 stars4.51.00.03.93.23.30.6IBRXImmunityBio2.1419 of 5 stars3.61.00.00.02.41.70.6RGCRegencell Bioscience0.3382 of 5 stars0.03.00.00.02.90.00.0VRNAVerona Pharma PLC American Depositary Share2.2695 of 5 stars2.15.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$61.2029.92% UpsideIBRXImmunityBio 3.20Buy$12.25346.27% UpsideRGCRegencell Bioscience 0.00N/AN/AN/AVRNAVerona Pharma PLC American Depositary Share 2.15Hold$109.004.03% UpsideCurrent Analyst Ratings BreakdownLatest IBRX, RGC, VRNA, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $68.007/14/2025BBIOBridgeBio PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.007/14/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.007/11/2025BBIOBridgeBio PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $67.007/10/2025VRNAVerona Pharma PLC American Depositary SharePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$138.00 ➝ $107.007/10/2025VRNAVerona Pharma PLC American Depositary ShareBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/9/2025VRNAVerona Pharma PLC American Depositary ShareCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold7/9/2025BBIOBridgeBio PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$60.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M40.31N/AN/A($7.71) per share-6.11IBRXImmunityBio$14.74M164.37N/AN/A($0.57) per share-4.82RGCRegencell BioscienceN/AN/AN/AN/A$0.02 per shareN/AVRNAVerona Pharma PLC American Depositary Share$42.28M210.96N/AN/A$2.56 per share40.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.58N/AN/AN/A-1,310.30%N/A-121.88%8/11/2025 (Estimated)RGCRegencell Bioscience-$4.30MN/A0.00∞N/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,492.50N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest IBRX, RGC, VRNA, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025IBRXImmunityBio-$0.10N/AN/AN/A$21.95 millionN/A8/7/2025Q2 2025BBIOBridgeBio Pharma-$0.50N/AN/AN/AN/AN/A8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share$0.39N/AN/AN/A$68.24 millionN/A5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million4/29/2025Q1 2025VRNAVerona Pharma PLC American Depositary Share-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.574.54IBRXImmunityBioN/A2.222.05RGCRegencell BioscienceN/AN/AN/AVRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%IBRXImmunityBio8.58%RGCRegencell Bioscience0.13%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%IBRXImmunityBio76.79%RGCRegencell BioscienceN/AVRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableIBRXImmunityBio590882.62 million204.86 millionOptionableRGCRegencell Bioscience10N/AN/AN/AVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableIBRX, RGC, VRNA, and BBIO HeadlinesRecent News About These CompaniesWeathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now2 hours ago | zacks.comJacobson & Schmitt Advisors LLC Lowers Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)3 hours ago | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given "Neutral" Rating at HC WainwrightJuly 16 at 3:01 AM | americanbankingnews.comHC Wainwright & Co. Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)July 15 at 11:46 PM | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15 at 11:46 PM | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15 at 1:01 PM | zacks.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)July 14 at 7:07 PM | globenewswire.comPharmaceutical Stocks To Research - July 14thJuly 14 at 2:47 PM | marketbeat.comTimesSquare Capital Management LLC Acquires New Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14 at 8:50 AM | marketbeat.comHC Wainwright Reiterates "Neutral" Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14 at 8:45 AM | marketbeat.comRice Hall James & Associates LLC Has $52.25 Million Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14 at 6:34 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to "Hold" at BTIG ResearchJuly 13 at 2:35 AM | americanbankingnews.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to Hold at Roth CapitalJuly 13 at 2:35 AM | americanbankingnews.comVERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNAJuly 12, 2025 | businesswire.comBTIG Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)July 12, 2025 | msn.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to "Hold" at Wolfe ResearchJuly 12, 2025 | marketbeat.comDiversify Wealth Management LLC Acquires 3,572 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 12, 2025 | marketbeat.comAlps Advisors Inc. Sells 5,993 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 12, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Rating Lowered to Hold at Wells Fargo & CompanyJuly 12, 2025 | americanbankingnews.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock Rating Lowered by TD CowenJuly 12, 2025 | americanbankingnews.comVerona Pharma PLC American Depositary Share's (VRNA) Hold Rating Reiterated at Jefferies Financial GroupJuly 12, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIBRX, RGC, VRNA, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$47.10 +0.14 (+0.29%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.ImmunityBio NASDAQ:IBRX$2.74 +0.01 (+0.18%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Regencell Bioscience NASDAQ:RGC$14.68 +0.98 (+7.15%) As of 12:02 PM EasternRegencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$104.78 +0.01 (+0.00%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
